Values of CA199, CA242, CEA, and CA125 in Diagnosis and Prognosis for Pancreatic Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LI Ning , SHEN Shiqiang , LIU Jianchao.

Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China;

Corresponding author：

Keywords：

Pancreatic cancer; Tumor marker; Diagnosis; Prognosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo explore the values of CA19-9, CA242, CEA, and CA125 single or combined detection on clinical diagnosis and prognosis for patients with pancreatic cancer. MethodsSerum tumor markers CA199, CA242, CEA, and CA125 of 63 patients with pancreatic cancer, 33 patients with cancer of bile duct, and 27 patients with benign pancreatic disease were detected, and those patients were followed up after operation. ResultsThe levels of CA19-9, CA242, CEA, and CA125 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic disease and cancer of bile duct (P lt;0.05). The sensitivity of CA19-9 alone was the highest in the four tumor markers for the patients with pancreatic cancer 〔79.4% (50/63)〕, but the specificity (61.9%) was lower than that of CA242 (83.3%) and CEA (80.0%). The specificity of combined detection of CA199+CA242+CEA was the highest 〔93.3% (56/60)〕. The level of CA19-9 in carcinoma of body/tail of pancreas was significantly higher than that of carcinoma of pancreas head or whole pancreas (P lt;0.05). The serum levels of CA19-9 and CA242 in patients with stage Ⅳ were significantly higher than those in stage Ⅰ or Ⅱ/Ⅲ (P lt;0.05). Fifteen patients were lost to follow up, 48 patients were followed up 2－12 months with an average 6 months. The levels of CA242 and CA199 in patients with pancreatic cancer on 0.5 month and 3 months after operation were lower than those before operation (P lt;0.05). ConclusionsSingle detection of CA19-9 can improve the diagnostic sensitivity, and combined detection of tumor markers CA199+CA242+CEA can improve the diagnostic specificity. CA19-9 or CA242 is a valuable marker for evaluating treatment effects and estimating prognosis.

Citation： LI Ning,SHEN Shiqiang,LIU Jianchao.. Values of CA199, CA242, CEA, and CA125 in Diagnosis and Prognosis for Pancreatic Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2011, 18(3): 300-301. doi: Copy

1.	赵玉沛. 胰腺癌诊断与治疗的现状与未来 [J]. 中华肝胆外科杂志, 2009, 15(5): 321324.
2.	Ducreux M, Boige V, Goéré D, et al. The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure [J]. Best Pract Res Clin Gastroenterol, 2007, 21(6): 9971014．.
3.	Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances [J]. Expert Opin Investig Drugs, 2006, 15(11): 13951410.
4.	李波. 胰腺癌综合治疗现状 [J]. 中国普外基础与临床杂志, 2000, 6(6): 390392.
5.	Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality [J]. Ann Surg, 2002, 236(3): 355366．.
6.	赵明, 季晓鹏, 王善菊, 等. 肿瘤标志物CA199与CEA联检对胰腺癌的诊断意义 [J]. 放射免疫学杂志, 2003, 16(6): 355.
7.	张乐之, 龚燕芳, 屠振兴. 胰腺癌患者血清CA242定量测定及其意义 [J]. 胰腺病学, 2002, 2(1): 2021.
8.	Levy C, Lymp J, Angulo P, et al. The value of serum CA199 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis [J]. Dig Dis Sci, 2005, 50(9): 17341740.
9.	孙文辉. 血清CA125、CA242监测恶性肿瘤病情进展的临床研究 [J]. 中国肿瘤临床与康复, 1996, 3(4): 15,14.
10.	原新红, 田亚平, 郭广宏. 血清肿瘤标志物联合检测的评价 [J]. 军医进修学院学报, 2005, 26(5): 350351.
11.	Nakaizumi A, Uehara H, Takenaka A, et al. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy [J]. Hepatogastroenterology, 1999, 46(25): 3137.
12.	吴本俨, 朱鸣, 蔡昌豪, 等. 老年胰腺癌临床诊治分析 [J]. 军医进修学院学报, 2004, 25(4): 307308.
13.	张群华, 倪泉兴. 胰腺癌2 340例临床病例分析 [J]. 中华医学杂志, 2004, 84(3): 214218.
14.	张太平, 赵玉沛, 蔡力行, 等. 肿瘤标记物联合检测在胰腺癌诊断及随访中的应用 [J]. 中华肝胆外科杂志, 1999, 5(2): 100102.
15.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [J]. CA Cancer J Clin, 2008, 58(2): 7196．.
16.	Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer [J]. Hepatobiliary Panereat Dis Int, 2004, 3(3): 464468．.
17.	王春友, 赵刚. 胰腺癌发生机制研究进展 [J]. 中华实验外科杂志, 2009, 26(7): 825826．.
18.	Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA199, and CA242 in the diagnosis and prognosis of pancreatic cancer [J]. Eur J Surg Oncol, 2005, 31(2): 164169.
19.	瞿彩平. 肿瘤标志物联合检测在晚期恶性肿瘤诊疗中的价值(附112例临床分析) [J]. 中国肿瘤临床与康复, 2002, 9(3): 9798.
20.	郑岚, 张志祥, 洪波, 等. 阻塞性黄疸患者血清AFP、CA199、CA50的检测与分析 [J]. 放射免疫学杂志, 2003, 16(1): 4546.
21.	汪子伟, 王克义. 肿瘤的化验 [M]. 杭州: 杭州出版社, 2001: 72.
22.	Peterli R, MeyerWyss B, Herzog U, et al. CA199 has no value as a tumor marker in obstructive jaundice [J]. Schweiz Med Wochenschr, 1999, 129(3): 7779.
23.	华宇明, 倪泉兴, 傅德良, 等. 胰腺癌血清肿瘤标记物的表达及其临床意义 [J]. 中国普外基础与临床杂志, 2001, 8(6): 387389.
24.	刘续宝. 胰腺癌根治性手术的再认识和展望 [J]. 中国普外基础与临床杂志, 2006, 13(5): 500501.
25.	Ritts RE, Pitt HA. CA199 in pancreatic cancer [J]. Surg Oncol Clin N Am, 1998, 7(1): 93101.

1. 赵玉沛. 胰腺癌诊断与治疗的现状与未来 [J]. 中华肝胆外科杂志, 2009, 15(5): 321324.
2. Ducreux M, Boige V, Goéré D, et al. The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure [J]. Best Pract Res Clin Gastroenterol, 2007, 21(6): 9971014．.
3. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances [J]. Expert Opin Investig Drugs, 2006, 15(11): 13951410.
4. 李波. 胰腺癌综合治疗现状 [J]. 中国普外基础与临床杂志, 2000, 6(6): 390392.
5. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality [J]. Ann Surg, 2002, 236(3): 355366．.
6. 赵明, 季晓鹏, 王善菊, 等. 肿瘤标志物CA199与CEA联检对胰腺癌的诊断意义 [J]. 放射免疫学杂志, 2003, 16(6): 355.
7. 张乐之, 龚燕芳, 屠振兴. 胰腺癌患者血清CA242定量测定及其意义 [J]. 胰腺病学, 2002, 2(1): 2021.
8. Levy C, Lymp J, Angulo P, et al. The value of serum CA199 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis [J]. Dig Dis Sci, 2005, 50(9): 17341740.
9. 孙文辉. 血清CA125、CA242监测恶性肿瘤病情进展的临床研究 [J]. 中国肿瘤临床与康复, 1996, 3(4): 15,14.
10. 原新红, 田亚平, 郭广宏. 血清肿瘤标志物联合检测的评价 [J]. 军医进修学院学报, 2005, 26(5): 350351.
11. Nakaizumi A, Uehara H, Takenaka A, et al. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy [J]. Hepatogastroenterology, 1999, 46(25): 3137.
12. 吴本俨, 朱鸣, 蔡昌豪, 等. 老年胰腺癌临床诊治分析 [J]. 军医进修学院学报, 2004, 25(4): 307308.
13. 张群华, 倪泉兴. 胰腺癌2 340例临床病例分析 [J]. 中华医学杂志, 2004, 84(3): 214218.
14. 张太平, 赵玉沛, 蔡力行, 等. 肿瘤标记物联合检测在胰腺癌诊断及随访中的应用 [J]. 中华肝胆外科杂志, 1999, 5(2): 100102.
15. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [J]. CA Cancer J Clin, 2008, 58(2): 7196．.
16. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer [J]. Hepatobiliary Panereat Dis Int, 2004, 3(3): 464468．.
17. 王春友, 赵刚. 胰腺癌发生机制研究进展 [J]. 中华实验外科杂志, 2009, 26(7): 825826．.
18. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA199, and CA242 in the diagnosis and prognosis of pancreatic cancer [J]. Eur J Surg Oncol, 2005, 31(2): 164169.
19. 瞿彩平. 肿瘤标志物联合检测在晚期恶性肿瘤诊疗中的价值(附112例临床分析) [J]. 中国肿瘤临床与康复, 2002, 9(3): 9798.
20. 郑岚, 张志祥, 洪波, 等. 阻塞性黄疸患者血清AFP、CA199、CA50的检测与分析 [J]. 放射免疫学杂志, 2003, 16(1): 4546.
21. 汪子伟, 王克义. 肿瘤的化验 [M]. 杭州: 杭州出版社, 2001: 72.
22. Peterli R, MeyerWyss B, Herzog U, et al. CA199 has no value as a tumor marker in obstructive jaundice [J]. Schweiz Med Wochenschr, 1999, 129(3): 7779.
23. 华宇明, 倪泉兴, 傅德良, 等. 胰腺癌血清肿瘤标记物的表达及其临床意义 [J]. 中国普外基础与临床杂志, 2001, 8(6): 387389.
24. 刘续宝. 胰腺癌根治性手术的再认识和展望 [J]. 中国普外基础与临床杂志, 2006, 13(5): 500501.
25. Ritts RE, Pitt HA. CA199 in pancreatic cancer [J]. Surg Oncol Clin N Am, 1998, 7(1): 93101.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Values of CA199, CA242, CEA, and CA125 in Diagnosis and Prognosis for Pancreatic Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content